Old Web
English
Sign In
Acemap
>
authorDetail
>
Javier Pascual
Javier Pascual
Institute of Cancer Research
Palbociclib
PI3K/AKT/mTOR pathway
Phosphatidylinositol
Gene isoform
Pathology
2
Papers
7
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
2019
Journal of Clinical Oncology
Juanita Lopez
Manuel SelviMiralles
Malaka Ameratunga
Anna Minchom
Javier Pascual
Udai Banerji
Hannah Bye
Florence I. Raynaud
Karen E Swales
Jason Malia
Michael Hubank
Isaac Garcia-Murillas
Mona Parmar
Sarah Emily Ward
Laura Finneran
Emma Hall
Alison Joanne Turner
Johann S. de Bono
Timothy A. Yap
Nicholas C. Turner
Show All
Source
Cite
Save
Citations (2)
PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.
2019
Journal of Clinical Oncology
Javier Pascual
Iain R. Macpherson
Anne C Armstrong
Sarah Emily Ward
Mona Parmar
Alison Joanne Turner
Hannah Bye
Paula Proszek
Andrew Dodson
Isaac Garcia-Murillas
Jenny King
Emma Hall
Laura Finneran
Juanita Lopez
A. Okines
Alistair Ring
Nicholas C. Turner
Show All
Source
Cite
Save
Citations (5)
1